Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia.

Nicoletti F, Orlando R, Di Menna L, Cannella M, Notartomaso S, Mascio G, Iacovelli L, Matrisciano F, Fazio F, Caraci F, Copani A, Battaglia G, Bruno V.

Front Psychiatry. 2019 Feb 14;10:49. doi: 10.3389/fpsyt.2019.00049. eCollection 2019. Review.

2.

Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.

Maksymetz J, Moran SP, Conn PJ.

Mol Brain. 2017 Apr 26;10(1):15. doi: 10.1186/s13041-017-0293-z. Review.

3.

Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?

Caraci F, Battaglia G, Sortino MA, Spampinato S, Molinaro G, Copani A, Nicoletti F, Bruno V.

Neurochem Int. 2012 Sep;61(4):559-65. doi: 10.1016/j.neuint.2012.01.017. Epub 2012 Jan 25. Review.

PMID:
22306345
4.

Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.

Caraci F, Molinaro G, Battaglia G, Giuffrida ML, Riozzi B, Traficante A, Bruno V, Cannella M, Merlo S, Wang X, Heinz BA, Nisenbaum ES, Britton TC, Drago F, Sortino MA, Copani A, Nicoletti F.

Mol Pharmacol. 2011 Mar;79(3):618-26. doi: 10.1124/mol.110.067488. Epub 2010 Dec 15.

PMID:
21159998
5.

[Targeting metabotropic glutamate receptors to develop novel antipsychotics].

Chaki S, Yoshida S, Okuyama S.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Nov;30(5-6):207-13. Review. Japanese.

PMID:
21226317
6.

Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.

Niswender CM, Jones CK, Lin X, Bubser M, Thompson Gray A, Blobaum AL, Engers DW, Rodriguez AL, Loch MT, Daniels JS, Lindsley CW, Hopkins CR, Javitch JA, Conn PJ.

ACS Chem Neurosci. 2016 Sep 21;7(9):1201-11. doi: 10.1021/acschemneuro.6b00036. Epub 2016 Aug 5.

7.

Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.

Litim N, Morissette M, Di Paolo T.

Neuropharmacology. 2017 Mar 15;115:166-179. doi: 10.1016/j.neuropharm.2016.03.036. Epub 2016 Apr 4. Review.

PMID:
27055772
8.

Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.

Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE.

Biochem Soc Trans. 2004 Nov;32(Pt 5):881-7. Review.

PMID:
15494040
9.
10.

Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators.

Yohn SE, Foster DJ, Covey DP, Moehle MS, Galbraith J, Garcia-Barrantes PM, Cho HP, Bubser M, Blobaum AL, Joffe ME, Cheer JF, Jones CK, Lindsley CW, Conn PJ.

Mol Psychiatry. 2018 Aug 16. doi: 10.1038/s41380-018-0206-2. [Epub ahead of print]

PMID:
30116027
11.

Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.

Walker AG, Conn PJ.

Curr Opin Pharmacol. 2015 Feb;20:40-5. doi: 10.1016/j.coph.2014.11.003. Epub 2014 Nov 27. Review.

12.

The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.

Stansley BJ, Conn PJ.

Curr Opin Pharmacol. 2018 Feb;38:31-36. doi: 10.1016/j.coph.2018.02.003. Epub 2018 Feb 24. Review.

13.

Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.

Sanger H, Hanna L, Colvin EM, Grubisha O, Ursu D, Heinz BA, Findlay JD, Vivier RG, Sher E, Lodge D, Monn JA, Broad LM.

Neuropharmacology. 2013 Mar;66:264-73. doi: 10.1016/j.neuropharm.2012.05.023. Epub 2012 May 30.

PMID:
22659090
14.

Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.

Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, Nicoletti F.

J Cereb Blood Flow Metab. 2001 Sep;21(9):1013-33. Review.

PMID:
11524608
15.

Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment.

WieroĊ„ska JM, Zorn SH, Doller D, Pilc A.

Pharmacol Ther. 2016 Jan;157:10-27. doi: 10.1016/j.pharmthera.2015.10.007. Epub 2015 Nov 5. Review.

PMID:
26549541
16.

Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.

Noetzel MJ, Rook JM, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, Xiang Z, Daniels JS, Jones CK, Lindsley CW, Weaver CD, Conn PJ.

Mol Pharmacol. 2012 Feb;81(2):120-33. doi: 10.1124/mol.111.075184. Epub 2011 Oct 21.

17.

Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.

Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.

J Med Chem. 2014 May 22;57(10):4154-72. doi: 10.1021/jm5000563. Epub 2014 May 9.

18.

Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.

Molinaro G, Traficante A, Riozzi B, Di Menna L, Curto M, Pallottino S, Nicoletti F, Bruno V, Battaglia G.

Mol Pharmacol. 2009 Aug;76(2):379-87. doi: 10.1124/mol.109.056580. Epub 2009 May 13.

PMID:
19439499
19.

Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.

Chaki S, Hikichi H.

Curr Pharm Des. 2011;17(2):94-102. Review.

PMID:
21355835
20.

Metabotropic glutamate receptors as therapeutic targets for schizophrenia.

Vinson PN, Conn PJ.

Neuropharmacology. 2012 Mar;62(3):1461-72. doi: 10.1016/j.neuropharm.2011.05.005. Epub 2011 May 19. Review.

Supplemental Content

Support Center